KBC Securities - Autolus Therapeutics ADS (AUTL) Autolus To assess feasibility of Cellares platform for CAR-T manufacturing

Report

KBC Securities

Jacob Mekhael

Autolus To assess feasibility of Cellares' platform for CAR-T manufacturing

Yesterday before US market opens, Autolus announced that it will assess the feasibility of Cellares' Cell Shuttle platform to complement its commercial manufacturing operations at the Nucleus facility in the UK. This evaluation could open the door for Autolus to expand its manufacturing to meet future demand from the larger autoimmune indications, which would likely require more than the 2000 batches per year capacity that the existing Nucleus facility is able to produce. $ 9 TP and BUY maintained.

07/01/2026 1 EN

Underlying

Autolus Therapeutics ADS

See profile

US05280R1005 NASDAQ Stock Market United Kingdom

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : MDXH BB, AUTL US, ENRGY BB

: MDXH BB, AUTL US, ENRGY BB

January 7, 2026 January 7, 2026 1 EN

GlobeNewsWire

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications SOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated Development and Manufacturing Organization (IDMO),...

January 6, 2026 January 6, 2026 1 EN

Morning Notes : ASRNL NA, BAR BB, CMBT BB

: ASRNL NA, BAR BB, CMBT BB

8h / 41m 8h / 41m 1 EN

Kristof Samoy

Kristof Samoy

CMB.Tech Intelligent asset disposal showcasing skill to time the cycle

CMBT struck the iron while it was hot and in line with its fleet rejuvenation strategy has been offloading 6 older VLCCs and two Capesizes. We estimate the aggregate disposal value at $500m. We expect the block sale to have occurred at firm prices absent discount -perhaps even exceeding our and Clarksons fair market values- considering the booming VLCC rates witnessed in 4Q25. Market rates in this segment were well above $100.000/day at numerous times past months. Half of the capital gain of $269m to be posted in 1Q26 (so $135m) will be distributed to shareholders while the remainder will be u...

8h / 59m 8h / 59m 1 EN

Jacob Mekhael

Jacob Mekhael

mdxhealth Collaboration with Oxford could further validate GPS in prostate cancer

Yesterday before US market opens, mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomised clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes. According to management, data publication is expected in 2026/2...

January 7, 2026 January 7, 2026 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Autolus To assess feasibility of Cellares' platform for CAR-T manufacturing

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : MDXH BB, AUTL US, ENRGY BB

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Morning Notes : ASRNL NA, BAR BB, CMBT BB

CMB.Tech Intelligent asset disposal showcasing skill to time the cycle

mdxhealth Collaboration with Oxford could further validate GPS in prostate cancer

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe